Sinalização PI3K/Akt/mTOR
Os inibidores da sinalização PI3K/Akt/mTOR são compostos que têm como alvo as vias da fosfoinositídeo 3-quinase (PI3K), da quinase Akt e do alvo da rapamicina em mamíferos (mTOR). Essas vias são reguladores críticos do crescimento celular, sobrevivência, metabolismo e autofagia, tornando-os alvos-chave na pesquisa de câncer e distúrbios metabólicos. A inibição dessas vias pode ajudar a controlar o crescimento e a proliferação tumoral, oferecendo estratégias terapêuticas potenciais para vários tipos de câncer e outras doenças caracterizadas por sinalização celular desregulada. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de alta qualidade de PI3K/Akt/mTOR para apoiar sua pesquisa em oncologia, sinalização celular e doenças metabólicas.
Subcategorias de "Sinalização PI3K/Akt/mTOR"
- AMPK(158 produtos)
- ATM/ATR(71 produtos)
- DNA-PK(51 produtos)
- EGFR(572 produtos)
- MELK(7 produtos)
- PDK(9 produtos)
- PI3K(242 produtos)
- S6 Quinase(9 produtos)
- gsk-3(112 produtos)
- mTOR(144 produtos)
Exibir 2 mais subcategorias
Foram encontrados 1038 produtos de "Sinalização PI3K/Akt/mTOR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
BX-320
CAS:<p>BX-320, a PDK1 inhibitor (IC50=30nM), selectively blocks Akt/p70S6K1 phosphorylation, induces apoptosis, and inhibits cancer cell growth.</p>Fórmula:C23H31BrN8O3Cor e Forma:SolidPeso molecular:547.45BEBT-109
CAS:<p>BEBT-109 is a selective epidermal growth factor receptor (EGFR) inhibitor that shows anti-tumor activity in EGFR-mutant non-small cell lung cancer.</p>Fórmula:C27H32N8O3Pureza:97.26%Cor e Forma:SolidPeso molecular:516.6EGFR-IN-30
CAS:<p>EGFR-IN-30 is an EGFR inhibitor (IC50: 1-10 nM, <1 nM WT/mutants) with potential in cancer research.</p>Fórmula:C28H33BrN7O2PCor e Forma:SolidPeso molecular:610.49EGFR-IN-61
CAS:<p>EGFR-IN-61 inhibits EGFR kinase (IC50: 42 nM L858R/T790M, 137 nM L858R/T790M/C797S, 743 nM WT) and slows A549 & H1975 cell growth (IC50: 2.14 & 1.82 μM).</p>Fórmula:C33H37ClN8O3Pureza:98%Cor e Forma:SolidPeso molecular:629.15EGFR-IN-85
CAS:<p>EGFR-IN-85 (Compound 1), an EGFR inhibitor, exhibits potent activity with an IC50 of 0.19 μM against EGFRvⅢ phosphorylation and can suppress intratumoral EGFR</p>Fórmula:C26H30N8O2Pureza:98%Cor e Forma:SolidPeso molecular:486.57JGK-068S
CAS:<p>Compound I (JGK-068S) is a potent inhibitor of the epidermal growth factor receptor (EGFR) [1].</p>Fórmula:C22H23BrFN5O2Pureza:98%Cor e Forma:SolidPeso molecular:488.35PI3K/mTOR Inhibitor-12
CAS:<p>PI3K/mTOR Inhibitor-12: oral, potent, selective; IC50: PI3Kα 0.06 nM, mTOR 3.12 nM; strong antitumor; less liver toxicity.</p>Fórmula:C27H27F2N9O4SPureza:98%Cor e Forma:SolidPeso molecular:611.62Simotinib
CAS:<p>Simotinib (AL-6802) is an EGFR tyrosine kinase inhibitor (IC50 : 19.9 nM) with antitumour activity for the study of non-small cell lung cancer.</p>Fórmula:C25H26ClFN4O4Pureza:99.7%Cor e Forma:SolidPeso molecular:500.95EGFR/CSC-IN-1
CAS:<p>EGFR/CSC-IN-1 is a dual inhibitor targeting both the epidermal growth factor receptor (EGFR [IC50 10.52 nM]) and cancer stem cells (CSC), with potential</p>Fórmula:C54H54Cl2FN7O7S2Pureza:98%Cor e Forma:SolidPeso molecular:1067.082′-Thioadenosine
CAS:<p>2'-Thioadenosine (PD157432) serves as a selective and irreversible inhibitor of ErbB-1 and ErbB-2 tyrosine kinases, demonstrating an IC50 value of 45 µM against</p>Fórmula:C10H13N5O3SPureza:98%Cor e Forma:SolidPeso molecular:283.31DZD1516
CAS:<p>DZD1516, a potent and selective HER2 inhibitor (IC50 = 0.56 nM), demonstrates good blood-brain barrier permeability and exhibits antitumor activity in both</p>Fórmula:C28H27F2N7O3Pureza:98%Cor e Forma:SolidPeso molecular:547.56EGFR mutant-IN-1
<p>EGFR mutant-in-1, a 5-methylpyrimidopyridone, selectively inhibits EGFRL858R/T790M/C797S mutants with an IC50 of 27.5 nM, lessening EGFRWT impact.</p>Fórmula:C34H39ClFN7O2Pureza:98%Cor e Forma:SolidPeso molecular:632.17GSK-3β inhibitor 8
CAS:<p>GSK-3β inhibitor 8 (GSK3β Inhibitor XVIII) is a potent and selective GSK-3β inhibitor with an IC50 value of 64 nM.GSK-3β inhibitor 8 is a thienopyrimidine</p>Fórmula:C20H20ClN5OSPureza:98.46%Cor e Forma:SolidPeso molecular:413.92EGFR-IN-36
CAS:<p>EGFR-IN-36 inhibits EGFR, HER2, & mutants with IC50s: 19.09 nM (EGFR WT), 120.01 nM (HER2 WT), 2.35 nM (HER2 mutant).</p>Fórmula:C26H25ClN6O2Cor e Forma:SolidPeso molecular:488.97EGFR-IN-32
CAS:<p>EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)</p>Fórmula:C31H34N6O3Cor e Forma:SolidPeso molecular:538.64AMPK-α1β1γ1 activator 1
CAS:<p>AMPK-α1β1γ1 activator 1 (M1), an acyl glucuronide metabolite derived from an Indole-3-carboxylic Acid-based AMPK activator, selectively activates the β1</p>Fórmula:C25H24ClNO9Pureza:98%Cor e Forma:SolidPeso molecular:517.91EGFR-IN-87
CAS:<p>EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,</p>Fórmula:C28H33N7O2Pureza:98.64%Cor e Forma:SolidPeso molecular:499.61EGFR-IN-1 hydrochloride
CAS:<p>EGFR-IN-1 HCl targets L858R/T790M EGFR mutants over wild-type; IC50: 4 nM in H1975, 28 nM in mutant HCC827 cells.</p>Fórmula:C28H31ClN6O4Pureza:99.16%Cor e Forma:SolidPeso molecular:551.04BGB-8035
CAS:<p>BGB-8035 is a BTK inhibitor with antitumor activity that inhibits BTK, TEC, and EGFR.BGB-8035 is used in the study of tumors and autoimmune diseases.</p>Fórmula:C24H31N5O4Pureza:96.74%Cor e Forma:SolidPeso molecular:453.53EGFR/ErbB-2 inhibitor-1
CAS:<p>EGFR/ErbB-2 inhibitor-1 is a selective ErbB2/HER2 inhibitor that effectively blocks ErbB2 and HER2 signaling.</p>Fórmula:C23H15ClFN3OS2Pureza:98.93%Cor e Forma:SolidPeso molecular:467.97Sevabertinib
CAS:<p>Sevabertinib (BAY 2927088) is an EGFR tyrosine kinase inhibitor, with anticancer activity, used in research on non-small cell lung cancer.</p>Fórmula:C24H25ClN4O5Pureza:99.81%Cor e Forma:SolidPeso molecular:484.93Rheb inhibitor NR1
CAS:<p>Rheb inhibitor NR1 is a Rheb inhibitor and selective mTORC1 inhibitor that promotes phosphorylation of S473pAKT.</p>Fórmula:C25H19BrCl2N2O3SPureza:99.72%Cor e Forma:SolidPeso molecular:578.3PI3K-IN-54
CAS:<p>Compound 10w, a substituted pyrazolo[1,5-a]pyrimidinamide compound, is a ZSTK474 analog that shows anticancer activity against HeLa cells.</p>Fórmula:C20H24F2N8O3Pureza:98.15%Cor e Forma:SolidPeso molecular:462.45GSK-F1
CAS:<p>GSK-F1 (PI4KA inhibitor-F1) is a novel potent PI4KA inhibitor.</p>Fórmula:C27H18F5N5O4SPureza:97.03%Cor e Forma:SolidPeso molecular:603.52PF-04979064
CAS:<p>PF-04979064 is a potent and selective PI3K and mTOR dual kinase inhibitor(Ki of 0.13 nM and 1.42 nM,respectively).</p>Fórmula:C24H26N6O3Pureza:98.20% - ≥98%Cor e Forma:SolidPeso molecular:446.5PKI-402
CAS:<p>PKI-402 is a potent PI3K and mTOR inhibitor. PKI-402 inhibits PI3Kα, mTOR, PI3Kβ, PI3Kδ and PI3Kγ with IC50s of 2, 3, 7, 14 and 16 nM, respectively.</p>Fórmula:C29H34N10O3Pureza:99.94%Cor e Forma:SolidPeso molecular:570.65GSK-3 inhibitor 1
CAS:<p>GSK-3 inhibitor 1 is a GSK-3 inhibitor.</p>Fórmula:C22H17ClFN5O2Pureza:98.42%Cor e Forma:SolidPeso molecular:437.85EGFR-IN-8
CAS:<p>EGFR-IN-8, a dual inhibitor targeting both EGFR and c-Met, shows potential as a promising candidate for further development in treating EGFR TKI-resistant NSCLC</p>Fórmula:C32H23ClF3N7O4Pureza:99.51%Cor e Forma:SolidPeso molecular:662.02GDC-0349
CAS:<p>GDC-0349 (RG-7603) is a potent and selective ATP-competitive inhibitor of mTOR, 790-fold inhibitory effect against PI3Kα and other 266 kinases. Phase 1.</p>Fórmula:C24H32N6O3Pureza:96.00% - 98.17%Cor e Forma:SolidPeso molecular:452.55GLPG3312
CAS:<p>GLPG3312 is a selective and potent pan-SIK inhibitor with the advantage of oral activity, for SIK1, SIK2 and SIK3, anti-inflammatory and immunomodulatory .</p>Fórmula:C23H21F2N5O3Pureza:98.53%Cor e Forma:SolidPeso molecular:453.44EGFR/HER2/DHFR-IN-1
<p>Potent EGFR/HER2/DHFR inhibitor for MCF-7 breast cancer; IC50: 0.153/0.108/0.291 μM; arrests G1/S phase, triggers apoptosis.</p>Fórmula:C14H11BrN4O2SCor e Forma:SolidPeso molecular:379.23DNA-PK-IN-15
CAS:<p>DNA-PK-IN-15 (compound 6) acts as an inhibitor of DNA-PK, exhibiting an IC50 value of 0.08 nM.</p>Fórmula:C23H23N9OCor e Forma:SolidPeso molecular:441.49HER2-IN-7
CAS:<p>HER2-IN-7 is a potent HER2 inhibitor with potential for researching ErbB-related diseases, especially cancer.</p>Fórmula:C28H26F3N7O3Cor e Forma:SolidPeso molecular:565.55EGFR-IN-160
CAS:<p>EGFR-IN-160 is an EGFR inhibitor with IC50 values of 1.62, 0.49, and 0.98 μM for EGFRWT, EGFRT790M, and EGFRL858R/T790M/C797S, respectively. It can induce cell cycle arrest at the G2/M and S phases and apoptosis (Apoptosis) in NCI-H522 cells, demonstrating anticancer properties. Additionally, EGFR-IN-160 exhibits antioxidant activity against DPPH (IC50: 12.11 µM) and H2O2 (IC50: 8.89 µM).</p>Fórmula:C15H12N2O4Cor e Forma:SolidPeso molecular:284.27EGFR/HER2-IN-4
<p>EGFR/HER2-IN-4: oral, irreversible dual EGFR inhibitor (IC50: 0.6 nM), targets L858R/T790M mutations, potent anti-lung cancer effects in vivo.</p>Cor e Forma:SolidEGFR-IN-147
CAS:<p>EGFR-IN-147 (compound ID-5841161) is a potent EGFR inhibitor, demonstrating a 14% inhibition rate at a concentration of 1μM. It holds promise for cancer research applications.</p>Fórmula:C13H13N5OCor e Forma:SolidPeso molecular:255.275EGFR/VEGFR2-IN-2
<p>EGFR/VEGFR2-IN-2 (compound 4b) serves as a dual inhibitor of VEGFR-2 and EGFR.</p>Fórmula:C24H15FO3Cor e Forma:SolidPeso molecular:370.37EGFR-IN-130
<p>EGFR-IN-130 (compound 14b) is an EGFR inhibitor and an inducer of apoptosis (apoptoosis). It effectively kills HeLa cancer cells by inducing apoptosis.</p>Fórmula:C27H25N3O6SCor e Forma:SolidPeso molecular:519.57LAS195319
CAS:<p>LAS195319 is a potent and selective inhaled PI3Kδ Inhibitor (IC50 = 0.5 nM) for the Treatment of Respiratory Diseases.</p>Fórmula:C29H26N10O3SCor e Forma:SolidPeso molecular:594.65EGFR-IN-23
CAS:<p>EGFR-IN-23, identified as compound 8 in WO2021244502A1, is a potent EGFR tyrosine kinase inhibitor (TKI) demonstrating an inhibitory concentration (IC50) of 8.</p>Fórmula:C36H44BrN10O3PCor e Forma:SolidPeso molecular:775.68iMDK quarterhydrate
<p>iMDK quarterhydrate, PI3K inhibitor, blocks MDK growth; suppresses NSCLC safely with MEK inhibitor.</p>Fórmula:C21H15FN2O3SCor e Forma:SolidPeso molecular:380.91ES-072
CAS:<p>ES-072, a selective inhibitor targeting the EGFR mutant (EGFR-T790M), is administered orally. By hindering EGFR-T790M activity, it activates GSK3α, which subsequently leads to the phosphorylation of PD-L1 at Ser279 and Ser283. This phosphorylation facilitates the recruitment of the E3 ubiquitin ligase ARIH1, resulting in the ubiquitination and proteasomal degradation of PD-L1. Such a process not only curtails the growth of cancer cells but also amplifies the anti-tumor immune response by diminishing PD-L1 levels. ES-072 has shown efficacy in impeding the proliferation of non-small cell lung cancer (NSCLC) cells.</p>Fórmula:C25H27F3N8O2Cor e Forma:SolidPeso molecular:528.53EGFR-IN-58
<p>EGFR-IN-58 is a potent, selective, ATP-competitive inhibitor of EGFR. EGFR-IN-58 exhibits significant cytotoxicity against melanoma, colon and blood cancers.</p>Fórmula:C31H30FN7OCor e Forma:SolidPeso molecular:535.61Tesevatinib tosylate
CAS:<p>Tesevatinib tosylate (XL-647 tosylate) is an orally administered epidermal growth factor receptor (EGFR) inhibitor that can cross the blood-brain barrier. It significantly reduces cell viability with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Additionally, Tesevatinib tosylate inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM), demonstrating antitumor activity by inhibiting tumor proliferation.</p>Fórmula:C31H33Cl2FN4O5SCor e Forma:SolidPeso molecular:663.59PI3Kδ-IN-23
CAS:<p>PI3Kδ-IN-23 (compound A11) is a potent inhibitor of PI3Kδ, with an IC50 of 0.27 nM. It binds to PI3Kδ through covalent interaction with Lys779 and plays a significant role in cancer research.</p>Fórmula:C30H30N6O5Cor e Forma:SolidPeso molecular:554.596DNA-PK-IN-6
CAS:<p>DNA-PK-IN-6 inhibits DNA-PKcs, disrupting tumor DNA repair and triggering apoptosis; enhances radiotherapy and targets various tumors (WO2021197159A1).</p>Fórmula:C19H21N7OCor e Forma:SolidPeso molecular:363.42EGFR/BRAF-IN-1
<p>EGFR/BRAF-IN-1 inhibits EGFR/BRAF (BRAFV600E IC50: 45 nM, GI50: 35 nM) and has antioxidant properties.</p>Fórmula:C26H28ClN3O4Cor e Forma:SolidPeso molecular:481.975-Bromo-3-indoxylacetate
CAS:<p>5-Bromo-3-indoxylacetate acts as an inhibitor of GSK-3, with a pIC50 value of 3.39.</p>Fórmula:C10H8BrNO2Cor e Forma:SolidPeso molecular:254.08HER2-IN-9
<p>HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.</p>Fórmula:C19H14BrF3N2OCor e Forma:SolidPeso molecular:423.23DNA-PK-IN-8
CAS:<p>DNA-PK-IN-8: Potent, selective oral DNA-PK inhibitor, IC50 = 0.8 nM, boosts anti-cancer effects with Doxorubicin.</p>Fórmula:C19H22N8O2Cor e Forma:SolidPeso molecular:394.43Andamertinib
CAS:<p>Andamertinib is an EGFR inhibitor with antitumor activity.</p>Fórmula:C31H36N8O3Cor e Forma:SolidPeso molecular:568.669EGFR-IN-135
<p>EGFR-IN-135 (compound 3d) is an EGFR inhibitor with an IC50 value of 0.086 µM. It inhibits cell growth and arrests the cell cycle in the S phase in breast cancer cell lines.</p>Fórmula:C12H14N4OS2Cor e Forma:SolidPeso molecular:294.4Tyrphostin 63
CAS:<p>Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.</p>Fórmula:C10H8N2OCor e Forma:SolidPeso molecular:172.183EGFR-IN-125
CAS:<p>EGFR-IN-125 (example 37) is a potent EGFR inhibitor with IC50 values of <0.3 nM for EGFR(d746-750/T790M/C797S), 0.52 nM for EGFR(L858R/T790M/C797S), 0.5 nM for EGFR(d746-750/C797S), 0.69 nM for EGFR(L858R/C797S), and 0.92 nM for EGFR (wild type).</p>Fórmula:C30H26N8OCor e Forma:SolidPeso molecular:514.58PI3K-IN-27
CAS:<p>PI3K-IN-27 is a potent PI3K inhibitor, relevant for cancer and immune disease research. See patent WO2021233227A1.</p>Fórmula:C30H26F2N6O2SCor e Forma:SolidPeso molecular:572.63PI3Kβ-IN-1
CAS:<p>PI3Kβ-IN-1 is a selective, orally active PI3Kβ inhibitor (IC50: 2 nM).</p>Fórmula:C25H14F2N8Cor e Forma:SolidPeso molecular:464.43ETP-47037
CAS:<p>ETP-47037: strong PI3Kα inhibitor (IC50: 0.99 nM), also targets PI3Kβ, δ, γ; may protect telomeres.</p>Fórmula:C20H27N9O3SCor e Forma:SolidPeso molecular:473.55GSK3-IN-9
CAS:<p>GSK3-IN-9 (0713) is a selective inhibitor of glycogen synthase kinase 3 (GSK3). It holds potential for research into fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood epilepsy, intellectual disabilities, diabetes, acute myeloid leukemia (AML), autism, and mental disorders.</p>Fórmula:C18H20N4OCor e Forma:SolidPeso molecular:308.378EGFR-IN-48
<p>EGFR-IN-48: potent EGFR inhibitor, oral, IC50: 0.193-66.7 nM, blocks EGFR mutants & BaF3/PC-9 cell proliferation.</p>Cor e Forma:SolidEGFR-IN-34
<p>EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.</p>Fórmula:C26H27ClN6O2Cor e Forma:SolidPeso molecular:490.98PI3K-IN-26
CAS:<p>PI3K-IN-26 is an effective PI3K inhibitor. PI3K-IN-26 inhibits the proliferation of SU-DHL-6 cells, IC50= 36 nM.</p>Fórmula:C21H18N6OSCor e Forma:SolidPeso molecular:402.47EGFR-IN-133
CAS:<p>EGFR-IN-133 (Compound 24) serves as an inhibitor targeting various mutations of the EGFR, including the wild type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with respective IC50 values of 0.1, 0.044, 0.036, 0.04, and 0.054 nM. The compound exhibits favorable pharmacokinetic properties and high oral bioavailability.</p>Fórmula:C27H29F2N7O3Cor e Forma:SolidPeso molecular:537.56EGFR-IN-132
CAS:<p>EGFR-IN-132 (Compound 23) is an EGFR inhibitor effective against various EGFR mutations including the wild-type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with IC50 values of 1.6, 0.025, 0.019, 0.022, and 0.029 nM, respectively. This compound demonstrates favorable pharmacokinetics with high oral bioavailability.</p>Fórmula:C27H31N7O3Cor e Forma:SolidPeso molecular:501.58EGFR-IN-139
CAS:<p>EGFR-IN-139 (compound PD 18) is an EGFR inhibitor with IC50 values of 12.88 nM (wild type), 10.84 nM (L858R/T790M), and 42.68 nM (L858R/T790M/C797S). It demonstrates significant anticancer activity against the A549 and H1975 cancer cell lines, which express high levels of EGFR. EGFR-IN-139 exhibits strong selectivity for cancer cells and can be utilized in research on non-small cell lung cancer (NSCLC).</p>Fórmula:C27H25ClN2O4Cor e Forma:SolidPeso molecular:476.951Tarloxotinib bromide
CAS:<p>Tarloxotinib bromide (TH-4000) is an irreversible inhibitor of EGFR/HER2.</p>Fórmula:C24H24Br2ClN9O3Pureza:99.52%Cor e Forma:SolidPeso molecular:681.77Vps34-IN-3
<p>Vps34-IN-3 is a potent, selective, and orally bioavailable inhibitor of VPS34 kinase .</p>Fórmula:C14H20N4O2Cor e Forma:SolidPeso molecular:276.33EGFR-IN-18
<p>EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).</p>Fórmula:C33H28N6O3SCor e Forma:SolidPeso molecular:588.68PI3kδ inhibitor 1
CAS:<p>PI3kδ inhibitor 1 is a selective inhibitor of PI3Kδ (IC50 of 3.8 nM).</p>Fórmula:C28H33FN6O2Pureza:98%Cor e Forma:SolidPeso molecular:504.60PI4KIIIbeta-IN-11
CAS:<p>PI4KIIIbeta-IN-11 is a PI4KIIIβ inhibitor (mean pIC50=9.1) that can be used to study diseases caused by RNA viruses and Plasmodium falciparum.</p>Fórmula:C33H39N7O3Cor e Forma:SolidPeso molecular:581.71SST0116CL1
CAS:<p>SST0116CL1 is an HSP90 inhibitor (IC50: 0.21 μM) that targets the ATP-binding pocket of Hsp90, disrupting its chaperone function and leading to the degradation of client proteins (EGFR, CDK4, and AKT). It induces the degradation of Her2 in BT-474 cells (IC50: 0.2 μM) and exhibits antiproliferative activity, inhibiting tumor growth.</p>Fórmula:C22H31ClN4O6Cor e Forma:SolidPeso molecular:482.96EGFR-IN-149
CAS:<p>EGFR-IN-149 (Compound 3-OH) is an EGFR inhibitor with an IC50 value of 0.42 nM.</p>Fórmula:C16H15N3OSCor e Forma:SolidPeso molecular:297.375NS-062
CAS:<p>NS-062 is an orally effective, irreversible covalent inhibitor targeting EGFR, demonstrating antiproliferative activity in the resistant double mutant H1975 cells with an IC50 of 0.19 μM. It also exhibits antitumor activity in a murine H1975 xenograft model.</p>Fórmula:C28H30Cl2F2N6O4Cor e Forma:SolidPeso molecular:623.48PF-5177624
CAS:<p>PF-5177624 is a selective and potent PDK1 inhibitor inducing anti-tumor activity in breast cancer cells.</p>Fórmula:C25H25FN8O2Cor e Forma:SolidPeso molecular:488.52GSK-3β inhibitor 25
CAS:<p>GSK-3β inhibitor25 (Compound 6h) exhibits weak inhibitory activity against GSK-3β with an IC50 greater than 100 μM.</p>Fórmula:C16H15NOSCor e Forma:SolidPeso molecular:269.361EGFR-IN-159
CAS:<p>EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.</p>Fórmula:C21H23N3O5Cor e Forma:SolidPeso molecular:397.4244-FPBUA
CAS:<p>4-FPBUA, a semi-synthetic analog of lichen acid, enhances the functionality of cell-based blood-brain barriers (BBB) and increases the transport of β-amyloid (Aβ) in monolayer cells. Additionally, it acts as an inhibitor of mTOR, enhancing cellular autophagy (Autophagy) which can reverse BBB disruption in vivo, making it relevant for research in Alzheimer's disease.</p>Fórmula:C31H23FO7Cor e Forma:SolidPeso molecular:526.51DNA-PK-IN-2
CAS:<p>DNA-PK-IN-2 is an inhibitor of the DNA-PK enzyme complex, useful in cancer research.</p>Fórmula:C20H23N5O3Cor e Forma:SolidPeso molecular:381.43HER2-IN-8
CAS:<p>HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.</p>Fórmula:C26H25F2N9O3Cor e Forma:SolidPeso molecular:549.53NSC381467
CAS:<p>NSC381467: Potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Fórmula:C20H16O7Cor e Forma:SolidPeso molecular:368.34PD-M6
CAS:<p>PD-M6 is an mTOR PROTAC degrader with a DC50 of 4.8 μM, which facilitates the ubiquitination and degradation of mTOR. It inhibits the proliferation of cancer cell lines HeLa, MCF-7, and HepG2 with IC50 values of 11.3, 2.58, and 3.23 μM, respectively, and induces autophagy. Additionally, PD-M6 specifically targets the degradation of the key protein LAMTOR1 in the mTOR signaling pathway.</p>Fórmula:C30H39N9O6Cor e Forma:SolidPeso molecular:621.69BPI-15086
CAS:<p>BPI-15086 is an orally active, effective, irreversible inhibitor selective for mutations, targeting both EGFR and the T790M resistance mutation tyrosine kinase. It can be utilized in the study of non-small cell lung cancer.</p>Fórmula:C29H33ClN8O4Cor e Forma:SolidPeso molecular:593.08BML-265
CAS:<p>BML-265 is a potent inhibitor of EGFR tyrosine kinase (EGFR tyrosine kinase). It disrupts Golgi apparatus integrity in human cells and hinders the transport of secretory proteins across various substances. In contrast, BML-265 does not affect the integrity and transport of the Golgi apparatus in rodent cells.</p>Fórmula:C18H15N3O2Cor e Forma:SolidPeso molecular:305.331GSK3β-IN-2
CAS:<p>GSK3β-IN-2 (Compound S01) is an inhibitor of GSK3β with an IC50 of 0.35 nM. It activates the Wnt/β-catenin signaling pathway, promoting neurogenesis and neurite outgrowth. GSK3β-IN-2 reduces tau protein phosphorylation induced by Aβ at the Ser396 site, thereby decreasing neurofibrillary tangles. Furthermore, GSK3β-IN-2 improves Alzheimer's disease symptoms in a zebrafish model.</p>Fórmula:C25H18N4OCor e Forma:SolidPeso molecular:390.437PI3K-IN-37
CAS:<p>PI3K-IN-37 inhibits PI3K α/β/δ (IC50: 6/8/4 nM) and mTOR (IC50: 4 nM).</p>Fórmula:C25H26N6O2Cor e Forma:SolidPeso molecular:442.51DNA-PK-IN-9
<p>DNA-PK-IN-9 (YK6) is a potent DNA-PK inhibitor with an IC50 of 10.47 nM, important in cancer research.</p>Fórmula:C21H21N5O2Cor e Forma:SolidPeso molecular:375.42EGFR/HER2-IN-5
<p>EGFR/HER2-IN-5: Irreversible, oral dual EGFR inhibitor, IC50 0.6 nM, targets L858R/T790M mutations, anti-tumor in vivo for lung cancer study.</p>Cor e Forma:SolidEGFR-IN-24
<p>EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).</p>Fórmula:C30H35FN6O3Cor e Forma:SolidPeso molecular:546.64NU5455
CAS:<p>NU5455 is a potent DNA-PKcs inhibitor, oral, boosts doxorubicin in liver tumors, amplifies topoisomerase inhibitors, no adverse effects.</p>Fórmula:C34H33N3O5SCor e Forma:SolidPeso molecular:595.71EGFR/HER2-IN-8
<p>EGFR/HER2-IN-8 inhibits EGFR, HER2, DHFR (IC50: 0.45, 0.244, 5.669 μM); useful in cancer research, safe and selective.</p>Fórmula:C16H16N4O2SCor e Forma:SolidPeso molecular:328.39D-69491 hydrochloride
CAS:<p>D-69491 hydrochloride is an inhibitor of HER-2 tyrosine kinase activity, blocking the phosphorylation of HER-2 and inhibiting the proliferation of SKOV-3 cells. It exhibits antitumor activity.</p>Fórmula:C25H26Cl2FN7O3Cor e Forma:SolidPeso molecular:562.42GSK3β-IN-1
CAS:<p>GSK3β-IN-1 (compound 1) is an inhibitor of glycogen synthase kinase-3β (GSK-3β) with an IC50 value of 65 nM, and it is utilized in Alzheimer's disease research.</p>Fórmula:C17H13FN2O4SCor e Forma:SolidPeso molecular:360.36GSK-3β inhibitor 7
<p>GSK-3β inhibitor 7 is a GSK-3β inhibitor (IC50: 5.25 μM).</p>Fórmula:C27H23BrN4O2SCor e Forma:SolidPeso molecular:547.47EGFR-IN-35
CAS:<p>EGFR-IN-35, an acrylamide-based EGFR inhibitor, shows promise for EGFR mutation-related cancers like NSCLC.</p>Fórmula:C25H24ClN7O2Cor e Forma:SolidPeso molecular:489.96GSK-3β inhibitor 26
CAS:<p>GSK-3β inhibitor26 (Compound D14) is a GSK-3β inhibitor with an IC50 of 18.23 μM. This compound is applicable in research related to cancer, inflammation, and neurodegenerative diseases.</p>Fórmula:C15H11N3O3Cor e Forma:SolidPeso molecular:281.266Pred17
<p>Pred17 is an effective EGFR inhibitor with potential applications in lung cancer research.</p>Fórmula:C27H22BN3OCor e Forma:SolidPeso molecular:415.29EGFR-IN-126
CAS:<p>EGFR-IN-126 (compound 9d) is an effective inhibitor of EGFR L858R/T790M/C797S, displaying an IC50 value of 0.005 μM. It exhibits antitumor activity both in vivo and in vitro.</p>Fórmula:C28H28BrFN4O3Cor e Forma:SolidPeso molecular:567.45SIK2-IN-3
CAS:<p>SIK2-IN-3 is an orally active selective inhibitor of SIK1/2 with IC50 values of 0.128/0.084 μM. It hinders the phosphorylation of CRTC3 and suppresses the production of pro-inflammatory factors in myeloid cells. Additionally, SIK2-IN-3 alleviates systemic and tissue inflammatory responses in a mouse anti-CD40 colitis model.</p>Fórmula:C23H24N6O2Cor e Forma:SolidPeso molecular:416.48HER2-IN-21
CAS:<p>HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.</p>Fórmula:C20H18N4O3SCor e Forma:SolidPeso molecular:394.447GSK-3β inhibitor 6
<p>GSK-3β inhibitor 6 is a highly potent inhibitor of GSK-3β, with an IC50 value of 24.4 μM.</p>Fórmula:C20H17BrN4Cor e Forma:SolidPeso molecular:393.28GSK-3β inhibitor 20
CAS:<p>GSK-3β inhibitor20 (compound 3A) is an effective inhibitor of GSK-3β, exhibiting an IC50 value of 74.4 nM.</p>Fórmula:C22H21N5O2SCor e Forma:SolidPeso molecular:419.50
